JP2022529806A - Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤 - Google Patents

Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤 Download PDF

Info

Publication number
JP2022529806A
JP2022529806A JP2021562811A JP2021562811A JP2022529806A JP 2022529806 A JP2022529806 A JP 2022529806A JP 2021562811 A JP2021562811 A JP 2021562811A JP 2021562811 A JP2021562811 A JP 2021562811A JP 2022529806 A JP2022529806 A JP 2022529806A
Authority
JP
Japan
Prior art keywords
compound according
groups
same
compound
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529806A5 (https=
Inventor
ジョン エル． マグナニ，
ジョン エム． ピーターソン，
アルン ケー． サーカー，
ユスフバーイ ユー． ヴォーラ，
ミュン－ギ ベク，
ホン－ウン ヤン，
Original Assignee
グリコミメティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコミメティクス， インコーポレイテッド filed Critical グリコミメティクス， インコーポレイテッド
Publication of JP2022529806A publication Critical patent/JP2022529806A/ja
Publication of JP2022529806A5 publication Critical patent/JP2022529806A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2021562811A 2019-04-24 2020-04-21 Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤 Pending JP2022529806A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838206P 2019-04-24 2019-04-24
US62/838,206 2019-04-24
PCT/US2020/029066 WO2020219417A1 (en) 2019-04-24 2020-04-21 Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors

Publications (2)

Publication Number Publication Date
JP2022529806A true JP2022529806A (ja) 2022-06-24
JP2022529806A5 JP2022529806A5 (https=) 2023-04-24

Family

ID=70680623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562811A Pending JP2022529806A (ja) 2019-04-24 2020-04-21 Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤

Country Status (9)

Country Link
US (1) US20230079833A1 (https=)
EP (1) EP3958978A1 (https=)
JP (1) JP2022529806A (https=)
KR (1) KR20220012246A (https=)
CN (1) CN114340736A (https=)
AU (1) AU2020263266A1 (https=)
BR (1) BR112021021244A2 (https=)
CA (1) CA3136661A1 (https=)
WO (1) WO2020219417A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3122321A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
ES3063748T3 (en) * 2019-07-31 2026-04-20 Crescent Biopharma Inc E-selectin antagonists for use in enhancing the survival of reconstituted, bone marrow-depleted hosts
US20230147312A1 (en) 2020-03-27 2023-05-11 Glycomimetics, Inc. Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin
WO2021247396A1 (en) 2020-05-31 2021-12-09 Magnani John L Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis
AU2021292458A1 (en) 2020-06-14 2023-01-19 GlycoMimetics Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
US20240269157A1 (en) 2021-08-03 2024-08-15 Glycomimetics, Inc. Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501840A (ja) * 2012-10-31 2016-01-21 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンアンタゴニスト化合物および使用方法
WO2018068010A1 (en) * 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097658A2 (en) 2002-05-16 2003-11-27 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
PL2264043T3 (pl) 2005-09-02 2018-04-30 Glycomimetics, Inc. Heterobifunkcyjne inhibitory pan-selektyny
EP2074132B1 (en) 2006-10-12 2013-05-15 GlycoMimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
ES2543063T3 (es) 2008-05-16 2015-08-14 Galecto Biotech Ab Nueva síntesis de inhibidores de galactósidos
KR102055958B1 (ko) 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
JP6689854B2 (ja) 2014-12-03 2020-04-28 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501840A (ja) * 2012-10-31 2016-01-21 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンアンタゴニスト化合物および使用方法
WO2018068010A1 (en) * 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists

Also Published As

Publication number Publication date
BR112021021244A2 (pt) 2021-12-21
KR20220012246A (ko) 2022-02-03
EP3958978A1 (en) 2022-03-02
CA3136661A1 (en) 2020-10-29
US20230079833A1 (en) 2023-03-16
CN114340736A (zh) 2022-04-12
WO2020219417A1 (en) 2020-10-29
AU2020263266A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
JP7304863B2 (ja) Ｅ－セレクチンおよびガレクチン－３のヘテロ二機能性阻害剤
JP2022529806A (ja) Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤
JP7272956B2 (ja) Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
KR102607640B1 (ko) 매우 강력한 다량체성 e-셀렉틴 길항물질
US20240150388A1 (en) Heterobifunctional inhibitors of e-selectin and galectin-3
JP7547345B2 (ja) ガレクチン－３阻害性ｃ－グリコシド
JP2016506386A (ja) 造血細胞の動員のためにｅ−セレクチンアンタゴニストを使用する化合物、組成物および方法
EP4003367B1 (en) E-selectin antagonists for use in enhancing the survival of reconstituted, bone marrow-depleted hosts
US20240287121A1 (en) Galectin-3 inhibiting c-glycoside oximes
JP2023508363A (ja) ガレクチン－３阻害性ｃ－グリコシドケトン、エーテル、およびアルコール
JP2024517936A (ja) ガレクチン－３阻害性ｃ－グリコシド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241112